Adoptive transfer of T cells engineered with a melanoma-specific T cell receptor (TCR) and inducible IL-18 resulted in enhanced antitumor T cell responses, hence suppressing melanoma growth in vivo [197]. The gene discussed is IL18; the disease is melanoma.